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Summary.
Consider a continuous marker for predicting a binary outcome. For example, serum
concentration of prostate speciﬁc antigen (PSA) may be used to calculate the risk of ﬁnding
prostate cancer in a biopsy. In this paper we argue that the predictive capacity of a marker
has to do with the population distribution of risk given the marker and suggest a graphical
tool, the predictiveness curve, that displays this distribution. The display provides a common
meaningful scale for comparing markers that may not be comparable on their original scales.
Some existing measures of predictiveness are shown to be summary indices derived from the
predictiveness curve. We develop methods for making inference about the predictiveness
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curve, for making pointwise comparisons between two curves and for evaluating covariate
eﬀects. Applications to risk prediction markers in cancer and cystic ﬁbrosis are discussed.
Key words: risk, classiﬁcation, explained variation, biomarker, ROC curve, prediction
1. Background
The Early Detection Research Network (EDRN) is a national network of biomarker devel-
opment laboratories and clinical centers sponsored by the National Cancer Institute (Vastag
2000). Two of its goals are to develop biomarkers for cancer screening and for cancer risk
prediction. The statistical focus in cancer screening is on the capacity of a marker to ac-
curately classify subjects as diseased or not (Pepe et al 2001). Classiﬁcation performance
parameters such as sensitivity and speciﬁcity are of key interest, because ultimately it is
the proportion of diseased subjects detected (sensitivity) and the proportion of non-diseased
subjects unnecessarily referred for work-up (1-speciﬁcity) that enter into decisions about
screening policy. The evaluation of markers for cancer risk prediction, however, requires a
diﬀerent approach. In this context we need to quantify how well a marker identiﬁes people at
high or low risk for cancer. A cancer risk prediction marker might be used to select subjects
for a prevention intervention or indeed for screening, but does not classify subjects directly.
Indeed Gail and Pfeiﬀer (2005) note that criteria for cancer risk prediction markers will often
be much less stringent than those required of screening markers.
In this paper we propose a graphical display to aid in the assessment of risk prediction
markers. The predictiveness curve shows the predictive capacity of a marker. An important
attribute is that it provides a common scale for comparing risk prediction markers. The
predictiveness curve has been suggested previously by Bura and Gastwirth (2001) and Copas
(1999), albeit with diﬀerent terminology. However, their focus was on inference for summary
indices. They did not address inference for the curve itself or comparisons between curves, nor
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did they consider curves for subpopulations deﬁned by covariates. In this paper, in addition
to addressing these points, we demonstrate the practical usefulness of the predictiveness
curve in assessing the value of risk prediction markers. We illustrate the methodology using
two datasets. The ﬁrst is a non-cancer application. It concerns major pulmonary infections
in children with cystic ﬁbrosis and the capacity of measures of lung function and nutritional
status to predict them. The second concerns prostate speciﬁc antigen (PSA), a widely used
biomarker for prostate cancer.
2. Predictiveness of a Binary Marker
Let D denote the binary outcome and denote the marker by Y . The risk associated with
marker value Y = y is
risk(y) ≡ P (D = 1|Y = y).
Throughout most of this paper we assume that larger values of Y are associated with in-
creasing risk, but generalize the ideas in Section 9. Although our interest is primarily in
evaluating continuous markers, we ﬁrst consider the simple setting when the marker is bi-
nary. In that case, subjects either have the lower risk level, risk(0) = P (D = 1|Y = 0), or
the higher value, risk(1) = P (D = 1|Y = 1).
Frequently the relative risk is used to summarize the predictiveness of a marker. However,
clearly the absolute levels of risk, not just their ratio, are important in describing the predic-
tive capacity of a marker. For example, a marker with relative risk equal to 10 may corre-
spond to absolute risks of (risk(0) = 0.1%, risk(1) = 1%) or (risk(0) = 1%, risk(1) = 10%).
These two scenarios have very diﬀerent implications if risks below 5% say are considered
unimportant and risks above 5% are considered “high.”
Reporting of absolute risks, however, is not suﬃcient either. The proportions of the
population who attain the lower and higher risk levels are also crucial components of pre-
dictiveness. For example, when seeking a marker that identiﬁes subjects at “high risk”, a
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marker with larger high risk prevalence, P [Y = 1], may be preferable even if the absolute
high risk value, risk(1), is somewhat smaller.
The deﬁnitions of “high” and “low” risk depend entirely on the clinical context and
include consideration of overall prevalence, consequences of disease, and interventions for
subjects in the low and high risk strata. In general, once appropriate thresholds have been
decided upon, one marker is preferable to another if it leaves fewer subjects in the interme-
diate equivocal risk range.
In conclusion, to fully describe the predictiveness of a binary marker, we stipulate that
one should report the absolute risks and the frequencies of those risks in the population.
That is, one should report the distribution of risk in the population conferred by the marker.
The remainder of this paper expands on this theme in relation to continuous markers.
3. The Predictiveness Curve
We propose the predictiveness curve, R(v) versus v, for describing the predictive capacity of
a marker where R(v) is the risk associated with the vth quantile of the marker:
R(v) = P [D = 1|Y = F−1(v)],
and F is the cumulative distribution function of the marker. Figure 1 displays curves for
−FEV1, a measure of lung function and −weight, a measure of nutritional status, for predict-
ing serious lung infection in the following year among cystic ﬁbrosis patients. The markers
are negated to conform to our convention that increasing values are associated with increas-
ing risk. Details of the data will be discussed in Section 7.
Observe that by using the scale v = F (Y ) on the x-axis, the markers are transformed to a
common scale. This facilitates their comparison, whereas on their original scales the markers
are not comparable. We see for example that at the 90th percentile of −FEV1, the risk is
0.76, whereas the risk is only 0.58 at the 90th percentile of −weight. Patients in the top
10% of the marker distribution are at greater risk when lung function rather than nutritional
4
http://biostats.bepress.com/uwbiostat/paper282
status is used as the risk prediction marker. Pulmonary function is also a better marker of
low risk. The bottom 10% have risks in the range (0.25, 0.28) according to −weight but in
a much lower range, (0.01,0.15) according to −FEV1.
Another way of looking at the predictiveness curve is to consider the inverse function.
We see that R−1(p) is the proportion of the population with risks less than or equal to
p. Suppose pL is a threshold that deﬁnes ‘low risk’ and pH is a threshold that deﬁnes
‘high risk.’ Then the proportions of the population with low, high, and equivocal risks are
R−1(pL), 1−R−1(pH) and R−1(pH)−R−1(pL), respectively. To illustrate in the cystic ﬁbrosis
example, suppose we take pH = 0.75 and pL = 0.25, then lung function is predictive of low
risk in R−1(0.25) = 29% of the population, of high risk in 1 − R−1(0.75) = 12% and it
leaves 59% of patients in the equivocal risk range. Nutritional status on the other hand is
completely uninformative about high or low risk. Knowledge of weight leaves all 100% of
patients with risks in the equivocal risk range, (0.25,0.75).
Interestingly, the predictiveness curve displays the distribution of risk(Y ) in the popula-
tion. As mentioned above, and most easily seen from the plot itself, R−1(p) is the proportion
of the population with risks less than p. Mathematically we write
R−1(p) = P [risk(Y ) < p]
is the cumulative distribution of risk(Y ). Correspondingly R(v) is the 100×vth percentile of
risk(Y ) in the population. We ﬁnd the display simple and useful for describing the predictive
capacity of a marker. It conveys the essential elements of our concept of predictiveness and
leads us to a general deﬁnition for the predictiveness of a marker in the population.
Definition. Predictiveness of Y ≡ the distribution of risk(Y )
A marker that is uninformative about risk assigns equal risk to all subjects, risk(Y ) =
P [D = 1|Y ] = P [D = 1] = ρ. The corresponding predictiveness curve is the horizontal line
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at R(v) = ρ, v ∈ (0, 1). On the other hand, a perfect marker assigns risk(Y ) = 1 for the
proportion ρ of subjects with D = 1 and risk(Y ) = 0 for the proportion 1− ρ with D = 0.
Correspondingly, its predictiveness curve is the step function R(v) = I [(1− ρ) < v], where
I [.] is the indicator function. Most risk prediction markers are imperfect, lying between these
extremes. Better markers have steeper curves corresponding to wider variation in risk. Note
that
∫
R(v)dv =
∫
P [D = 1|Y ]dF (Y ) = ρ. Therefore ∫ (R(v) − ρ)dv = 0, which implies
that
∫ v∗
0
(ρ − R(v))dv = ∫ 1
v∗(R(v)) − ρ)dv where v∗ is the point where R(v∗) = ρ. In other
words, the areas between the curve and the horizontal line at ρ that are above and below the
horizontal line are equal. The horizontal line at ρ serves as a useful benchmark and visual
aid in evaluating predictiveness curves.
4. Estimation
We now turn to the task of estimating the predictiveness curve. Suppose data from a random
sample of n independent identically distributed subjects are available, {(Yi, Di), i = 1, . . . , n}.
We model the risk as a parametric increasing function of Y into (0,1):
P [D = 1|Y ] = G(β, Y )
where G has the form of a cumulative distribution function (cdf). Assume that an asymp-
totically normal estimator of β is employed with var(
√
n(βˆ − β)) = Σ(β). For exam-
ple, βˆ might be the maximum likelihood estimate from a linear logistic model G(β, Y ) =
exp(β0 + βY )/{1 + exp(β0 + βY )}. We prefer to employ more ﬂexible models and use the
3 parameter Box-Cox family (Cole and Green, 1992) in our illustrations. Let Fˆ be the
empirical cdf of Y . Then
Rˆ(v) ≡ G(βˆ, Fˆ−1(v)) v(0, 1).
Theorem 1
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The asymptotic distribution of
√
n(Rˆ(v)−R(v)) is mean 0, normal, with variance σ2(v)
where
σ2(v) =
(
∂R(v)
∂β
)T
Σ(β)
(
∂R(v))
∂β
)
+ v(1− v)
(
∂R(v)
∂v
)2
(1)
and 0 < v < 1.
The result indicates that the variance of Rˆ(v) is comprised of two additive components.
The ﬁrst is due to variability in βˆ while the second is due to variability in Fˆ−1(v). Observe
that the magnitude of the second component depends on the slope of the predictiveness curve
at v. The variability due to Fˆ−1(v) is more important when R(v) is steep. It makes sense
intuitively that imprecision in Fˆ−1(v) will have a greater impact on Rˆ(v) when (∂/∂v)R(v)
is larger. Asymptotic theory for the inverse function is provided in the next result.
Theorem 2
√
n(Rˆ−1(p) − R−1(p)) has an asymptotically normal distribution with mean 0 and variance
τ 2(p) where
τ 2(p) =
[
∂R−1(p)
∂β
]T
Σ(β)
[
∂R−1(p)
∂β
]
+ R−1(p)(1− R−1(p)) (2)
and p is in the range of {R(v) : v(0, 1)}
The variance again is comprised of two additive components, one due to βˆ and the
other due to Fˆ . If β were known precisely, then Rˆ−1(p) is the binomial proportion of
subjects with risk(Y ) < p, so its variance is the binomial variance R−1(p)(1−R−1(p))/n as
indicated by (2). On the other hand, if F , the population distribution of Y , were known,
then Rˆ−1(p) = F (G−1(βˆ, p)), which only includes βˆ as a random variable, and its variance
is given by the ﬁrst component of (2). Observe also the simple relationship between τ 2(p)
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and σ2(v) at v = R−1(p): σ2(v) = ((∂/∂v)R(v))2τ 2(p). Variability in Rˆ−1(p) is magniﬁed by
(∂/∂v)R(v) on the scale for Rˆ(v).
Consistent estimates of σ2(v) and τ 2(p) are obtained by substituting estimated quan-
tities into expressions (1) and (2). Derivatives with respect to β of Rˆ(v) = G(β, Fˆ−1(v))
and Rˆ−1(p) = Fˆ (G−1(βˆ, p)) are easily obtained since G and G−1 are simple diﬀerentiable
functions of β. To estimate (∂/∂v)(R(v)) = [(∂/∂y)G(β, y)][(∂/∂v)F−1(v)] where y =
F−1(v), the ﬁrst component is straightforward while the second involves the density of Y ,
(∂/∂v)F−1(v) = 1/f(F−1(v)). We use a Gaussian kernel density estimate for f in our ap-
plications with bandwidth h optimal for normally distributed data (Silverman, 1986):h =
n−
1
51.06min(standard deviation, interquartile range/1.349).
5. Simulation Studies
We performed a limited simulation study to investigate the use of large sample inference for
R(v) and R−1(p) in ﬁnite sample studies. Data were simulated according to two models.
In the ﬁrst, F is a standard normal distribution and the risk function is linear logistic,
G(β, Y ) = exp(β0 + β1Y )/(1 + exp(β0 + β1Y )). We chose (β0, β1) such that R(0.1) and
R(0.9) were at pre-deﬁned values. In the second, F is standard log normal and the risk
function is from the Box-Cox family: G(β, Y ) = Φ(β0 + β1Y
(β2)) where Y (λ) = (Y λ − 1)/λ
when λ = 0 and Y (λ) = log Y when λ = 0. In this setting we ﬁxed β2 = −0.4, 0, or
0.4 and then chose (β0, β1) based on speciﬁed values for R(0.1) and R(0.9). We ﬁt the
predictiveness curves using the correct form for G(β, Y ). That is, we did not investigate the
robustness of these models to misspeciﬁcation. In practice one should check for goodness of
ﬁt, investigating multiple model forms if necessary.
Tables 1 and 2 show the results of our simulations for one of the Box-Cox model simu-
lations. We found that bias was minimal. Variance estimates reﬂected the actual sampling
variability with sample sizes of n = 500 or more. Consequently the coverage of 95% conﬁ-
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dence intervals was excellent in moderate to large samples but lower than the nominal level
with n = 100. Problems occurred only at the edges of the predictiveness curve, at v = 0.1
and v = 0.9. Considering that with n = 100 only 10 observations lay beyond these points,
the reduced performance under these circumstances seems reasonable. With larger sample
sizes, (n ≥ 500), inference based on asymptotic inference appeared to work very well across
all of the scenarios we studied (additional results not shown).
6. Further Inferential Techniques
6.1 Comparing Markers
A key attribute of the predictiveness curve is that it provides a common relevant scale
for comparing risk prediction markers. Here we consider formal comparisons between two
markers. Comparisons might be based on the diﬀerence in risk percentiles, RA(v0)−RB(v0),
at some v = v0 of interest where subscripts denote markers A and B. The Appendix
summarizes asymptotic distribution theory for RˆA(v)− RˆB(v), assuming that both markers
are measured on the same individuals. The estimated standard error of the diﬀerence is
calculated using steps analogous to those described earlier for calculating the estimated
standard error of Rˆ(v). A p-value can then be based on the Z-statistic: RˆA(v) − RˆB(v)
divided by the estimated standard error.
A particularly compelling case can be made for comparing markers on the basis of Rˆ−1(p)
where p is a threshold that deﬁnes high (or low) risk. One marker of high risk would be
preferred over another if it identiﬁes a greater fraction of people at high risk. That is, if the
high risk threshold is pH and R
−1
A (pH) − R−1B (pH) > 0 then marker B is a better marker of
high risk. Asymptotic distribution theory for Rˆ−1A (p) − Rˆ−1B (p), provided in the Appendix
can serve as the basis of conﬁdence intervals and hypothesis testing.
Our methodology concerns pointwise comparisons between markers. The simple clinically
relevant interpretations for points on the predictiveness curve and its inverse motivate making
such comparisons in practice. However, statistical power might be greater for statistics based
9
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on summary indices. Gail and Pfeiﬀer (2005) note that several indices of predictability are
functionals of the predictiveness curve. For example, the average entropy (Shapiro 1977) is
∫ {R(v) logR(v)+(1−R(v)) log(1−R(v))}dv and the risk variance is ∫ (R(v)−ρ)2dv. Both
give rise to measures of the proportion of explained variation (Mittlebock and Schemper,
1996) which are existing summary indices of predictiveness. Bura and Gastwrith (2001)
suggest the total gain, TG =
∫ |R(v) − ρ|dv, as a summary index. Methods for making
formal comparisons between predictiveness curves based on summary indices, however, have
not been studied yet. Bootstrapping could be used for inference in practice.
6.2 Covariate Specific Predictiveness Curves
The predictiveness of a marker can vary across populations. This can happen if the
marker distribution varies or if there is an interaction between the marker and a covariate
on risk. In addition, the usefulness of a risk prediction marker may vary with the overall
risk. In a low risk population, the marker may not identify any high risk subjects while in a
moderate risk population it might, even if the distribution of the marker and its association
with risk are the same. In this section we consider how to estimate predictiveness curves in
subpopulations deﬁned by covariates denoted by Z.
For a discrete covariate, one can simply stratify and estimate stratum speciﬁc predictive-
ness curves, RZ(v), as described earlier. More generally we model the eﬀect of Z on risk
with
P (D = 1|Y, Z) = G(β, Y, Z)
where, as before, G is monotone increasing in Y , and we use a semiparametric location-scale
model (Heagerty and Pepe, 1999) for the distribution of Y given Z
Fz(y) = P (Y ≤ y|Z = z) = F0
(
y − μz
σz
)
where μZ = γ
′
U(Z) and log(σZ) = δ
′W (Z), and U(Z) and W (Z) are speciﬁed functionals
of Z. For example, for binary Z, U(Z) and W (Z) could be (1, Z), while for continuous Z,
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U(Z) and W (Z) could be a B-spline basis for Z. Writing Ui = U(Zi) and Wi = W (Zi), the
estimators γˆ and δˆ are solutions to
n∑
i=1
Ui(Yi − γ′Ui)/σ2Zi = 0
n∑
i=1
Wi[(Yi − γ′Ui)2 − σ2Zi]/σ2Zi = 0.
Denoting the empirical cumulative distribution of standardized residuals by Fˆ0(·), the
Z=z covariate-speciﬁc marker distribution estimate is
Fˆz(y) = Fˆ0
(
y − γˆ′u
eδˆ′w
)
where u = U(z) and w = W (z). The corresponding vth quantile is
Fˆ−1z (v) = γˆ
′u + eδˆ
′wFˆ−10 (v).
Having ﬁt the risk model, through maximum likelihood or otherwise, the covariate speciﬁc
predictiveness curve estimate is
Rˆz(v) = G(βˆ, Fˆ
−1
z (v), z).
Similarly, the estimated inverse is
Rˆ−1z (p) = Fˆz(G
−1(βˆ, p, z)).
Asymptotic distribution theory is provided in the appendix.
7. The Cystic Fibrosis Data
Cystic ﬁbrosis is a genetic disorder that results in impaired ion transport across the cell
membrane. Its eﬀects on pulmonary and gastrointestinal systems lead to progressive deteri-
oration. Predicted survival currently extends into the mid 30s (Cystic Fibrosis Foundation,
2004). The main culminating event that leads to death is acute pulmonary exacerbation,
i.e., lung infection requiring intravenous antibiotics.
11
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To illustrate our methodology we use data from the Cystic Fibrosis Registry, a database
maintained by the Cystic Fibrosis Foundation, containing annually updated information on
over 20,000 people diagnosed with CF and living in the USA. We consider weight and FEV1
measured in 1995 to predict pulmonary exacerbations in 1996. Data for 11,960 patients are
analyzed of whom 5094 (42%) had at least one pulmonary exacerbation. Patients 6 years of
age and older are included. Weight is standardized for age and gender (Hamill et al., 1977)
and FEV1 is standardized for age, gender and height (Knudson et al., 1983). See Moskowitz
and Pepe (2004) for more details. Figure 1 shows the estimated predictiveness curves for
−FEV1 and −weight. We have referred to them as population curves earlier in the paper
when illustrating concepts but now acknowledge their sampling variability.
Table 3 shows point estimates and conﬁdence intervals for R(v) and R−1(p). We have
tight conﬁdence intervals for the estimates whose values were already mentioned in relation
to this curve in Section 3. Conﬁdence intervals calculated using bootstrap resampling were
almost identical to those based on asymptotic theory. The second column shows the %
variance in Rˆ(v) due to Fˆ , i.e., the second component of (1). Observe that it is larger for
−FEV1 than for −weight presumably because the predictiveness curve for −FEV1 is more
steep. An hypothesis test based on the diﬀerence in predictiveness estimates at v = .1 yields
p-value< 0.01. This test uses the asymptotic variance expression given in the Appendix. At
v = 0.9 the diﬀerence in R(v) for the two markers is also statistically signiﬁcant (p-value
< 0.01).
We next consider the predictiveness of lung function (Y = −FEV1) in subpopulations
deﬁned by their nutritional status (Z = weight). We modeled the risk of pulmonary exac-
erbation with the Box-Cox form
P [D = 1|Y, Z] = Φ(β0 + β1Y (λ) + β2Z)
and used a semiparametric location scale model for log(−Y ) with mean a natural cubic spline
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function of Z having knots at the 0.30 and 0.70 quantiles of Z and log standard derivation
also a natural cubic spline with knot at the median of Z. Fitted predictiveness curves are
shown in Figure 2 for subjects with weight at the median, ﬁrst and third quartiles. Observe
that the incidence of pulmonary exacerbation varies across these three populations, from
58% in subjects at the ﬁrst quartile of weight to 30% in subjects at the third quartile. In
the latter population, FEV1 identiﬁes .41 of subjects below the low risk threshold of 25%
(95% CI = (0.38,0.43)) but only 0.01 with risks above the high risk threshold of 75% (95%
CI=(0.01,0.02)). On the other hand, in the high risk population FEV1 identiﬁes only 0.06
(95% CI=(0.05,0.07)) low risk subjects and 0.23 (95% CI=(0.20,0.25)) high risk subjects.
Therefore FEV1 is a particularly useful marker of high risk in subjects at already somewhat
elevated risk due to their nutritional status and similarly it is more useful as a low risk
marker in subjects at somewhat reduced risk based on their weight.
8. Markers for Prostate Cancer
The Prostate Cancer Prevention Trial was a randomized prospective study of men with PSA
< 3.0 ng/mL, aged 55 years and older who were followed up for 7 years with annual PSA
measurements. A biopsy was recommended for all men either during or at the end of the
study. Thompson et al. (2006) identiﬁed 5519 men on the placebo arm of the trial who
had undergone prostate biopsy and had a PSA and digital rectal exam (DRE) during the
year prior to biopsy and at least 2 PSA values from the 3 years prior to biopsy. Prostate
cancer risk was evaluated as a function of PSA, PSA velocity and several other variables
including age, family history, DRE and prior prostate biopsy. Here we use the data to
compare PSA and PSA velocity as predictors of prostate cancer risk. 21.9% of men were
found to have prostate cancer. Figure 3 top panel displays the predictiveness curves for PSA
and PSA velocity. The curve for PSA velocity is more shallow, indicating that it is a poorer
marker of risk for this general class of prostate cancers. The 90thpercentile of risk is 0.291
13
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according to PSA velocity while it is higher, 0.369, according to the absolute most recent
PSA measurement (p < 0.01). At the low end of the scale, the 10thrisk percentiles based
on PSA velocity and PSA are 0.149 and 0.091 (p < 0.01) respectively, again suggesting that
PSA is the better marker of risk. According to PSA velocity 2.9% of men can be classiﬁed as
having risk below 10% while far more, 13.6%, qualify as low risk when using most recent PSA
as the marker (p < 0.01). In addition, a greater fraction are found to have risks above 30%
with PSA, 1− Rˆ−1(.30) = 23.0%, than with PSA velocity 1− Rˆ−1(0.30) = 8.0%(p < 0.01).
Prostate cancer biopsy specimens are classiﬁed using the Gleason scoring system with
higher scores associated with more aggressive disease. The bottom panel of Figure 3 shows
the same markers as predictors of high-grade prostate cancer (Gleason score ≥ 7) which
occurred in only 4.7% of men. Again, the 10thand 90thpercentiles of risk are better for
PSA than for PSA velocity. The 10thpercentiles are 0.4% versus 1.3% (p=0.05) and the
90thpercentiles are 11.1% versus 8.5% (p < .01) for the two markers. The proportion of
subjects with risks greater than 10% is 0.063 according to the PSA velocity marker while
the proportion is much larger, 0.132, according to the absolute PSA marker (p < 0.01). We
conclude that absolute PSA is also a better risk prediction marker than PSA velocity for
high grade prostate cancer.
9. Discussion
The predictiveness curve provides a complete and conceptually simple description of the ca-
pacity of a marker to predict risk. It is not an entirely new proposal. The idea of categorizing
a continuous marker according to quartiles or quintiles say and documenting the proportions
of subjects with D = 1 in each category is not uncommon in the applied literature (see
Willett et al., 1987 for example). Our proposal builds on and formalizes the idea, allowing
the marker scale to remain continuous and restricting the risk function to be monotone.
Our method has the added advantage that it provides inference about the inverse function,
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R−1(p) (or 1−R−1(p)) the proportion of the population with risks below (or above) p, which
are often of key interest.
Receiver operating characteristic curves generalize to continuous markers the notions of
sensitivity, P (Y = 1|D = 1), and speciﬁcity, P (Y = 0|D = 0), that are deﬁned for binary
markers. The idea is to use a threshold c to deﬁne a series of binary markers, “Y > c”, and
to plot the corresponding sensitivity versus 1−speciﬁcity for all values of c. In a similar vein,
Moskowitz and Pepe (2004) proposed generalizing the binary marker notions of positive and
negative predictive values, PPV = P (D = 1|Y = 1) and NPV = P (D = 0|Y = 0), to
continuous markers using thresholds. They proposed the positive predictive value (PPV)
curve, which is a plot of PPV(v) = P (D = 1|Y > F−1(v)) versus v. These curves are
mathematically related to the predictiveness curve
PPV(v) =
∫ 1
v
R(u)du/(1 − v).
In words, the PPV of the decision rule F (Y ) > v is the average risk(Y ) for Y that satisfy
the positivity criterion. We note that the PPV curve is concerned with the performance
of classiﬁcation rules, not directly with predictiveness. An estimated predictiveness curve
gives rise to an estimate of the predictive value curve. However, in contrast the empirical
nonparametric methods used by Moskowitz and Pepe (2004) to estimate the PPV curve do
not give rise to a simple estimate of R(v). Numerical derivatives are required and mononicity
cannot be guaranteed. Observe that neither ROC curves nor positive predictive value curves
show the population distribution of risk that is displayed by predictiveness curves.
A key element of our proposal is that risk(Y ) is monotone increasing. This allows us to
interpret R−1(p) as the proportion of the population with risks below p, and to say that a
proportion v of the population have risks below R(v). Some markers may not have monotone
increasing risk functions. To accommodate such markers a more general deﬁnition of the
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predictiveness curve can be provided:
R(v) = p : P [risk(Y ) ≤ p] = v (3)
That is, R(v) is the 100×vth percentile of risk(Y ) in the population. Equivalently, R−1(p) is
the cdf of the random variable risk(Y ). The ordering on the x-axis is according to risk(Y )
and is equivalent to that based on Y if risk(Y ) is a monotone increasing function. For
the more general case, one can ﬁt a risk model that allows non-monotonicity and plot the
empirical percentiles for Rˆ(v).
In most applications however, we expect that the risk function is monotone increasing
with the marker. Eﬃciency is likely gained by incorporating this restriction into the model.
We used the Box-Cox family of distributions to ﬁt monotone predictiveness curves to data.
This 3 parameter family is reasonably ﬂexible. It includes a wide variety of shapes (Cole and
Cole 1992). However, further research is required to determine if another parametric family
would be preferable. For ﬁtting non-monotone curves we prefer B-splines because of their
local nature and numerical stability. However analogues for ﬁtting monotone curves do not
appear to be available.
We have considered simple continuous prediction markers in this paper. However Y could
be a function of multiple markers and risk factors. It might be a clinical prediction score
derived from ﬁtting a risk model to data. We note that if the risk score is to be evaluated
with predictiveness curves estimated from the same data as used to develop the score, then
issues pertaining to shrinkage, (ie., overoptimism of Rˆ(v) estimated from the same data used
to develop the linear combination) would need to be addressed. We leave that for future
research.
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Appendix: Large Sample Distributions
Let
Ψ1i = −∂R(v)
∂v
(
I
[
Yi ≤ F−1(v)
]− v)
Ψ2i = I [G(β, Yi) ≤ p]− P [G(β, Y ) ≤ p] = I
[
Yi ≤ G−1(β, p)
]− R−1(p)
and assume
√
n(βˆn−β) = n− 12
∑n
i=1 Ψ3i + op(1), where Ψ3i, i = 1, ..., n are independently
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identically distributed variables with E(Ψ3i|Yi) = 0 and var(Ψ3i) ≡ Σ(β). Observe that Ψ1i
and Ψ2i are also mean zero random variables with variances v(1−v)
(
∂R(v)
∂v
)2
and R−1(p)(1−
R−1(p)), respectively. When v = R−1(p), Ψ1i = −∂R(v)∂v Ψ2i.
In the supplementary appendix we show
√
n
(
Rˆ(v)− R(v)
)
= n−1/2
(
∂R(v)
∂β
) n∑
i=1
Ψ3i + n
−1/2
n∑
i=1
Ψ1i + op(1)
√
n
(
Rˆ−1(p) −R−1(p)
)
= n−1/2
(
∂R−1(p)
∂β
) n∑
i=1
Ψ3i + n
−1/2
n∑
i=1
Ψ2i + op(1)
A.1 Comparing Markers
Subscripts A and B are used to denote the markers.
Result A.1
The asymptotic distribution of
√
n(RˆA(v) − RˆB(v) − (RA(v) − RB(v))) is normal with
mean 0 and variance
var
(
∂RA(v)
∂βA
Ψ3A − ∂RB(v)
∂βB
Ψ3B
)
+ var (Ψ1A −Ψ1B)
where βA and βB are the parameters in the risk models for P (D = 1|YA) and P (D = 1|YB)
respectively.
Result A.2
The asymptotic distribution of
√
n(Rˆ−1A (p)− Rˆ−1B (p))− (R−1A (p)−R−1B (p)) is normal with
mean 0 and variance
var
(
∂R−1A (p)
∂βA
Ψ3A − ∂R
−1
B (p)
∂βB
Ψ3B
)
+ var(Ψ2A −Ψ2B)
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Asymptotic variances can be estimated by substituting empirical or estimated quantities
as necessary.
A.2 Covariate Specific Predictiveness Curves
Result A.3
Since γˆ and δˆ are solutions to estimating equations we can write them as
√
n (γˆ − γ) ≡
n−1/2
∑
i=1 γi and
√
n
(
δˆ − δ
)
≡ n−1/2∑i=1 δi.
Let
Ψ1iz = −∂Rz(v)
∂v
(
I
(
Yi − γ′Ui
eδ′Wi
≤ F−10 (v)
)
− v
)
+
∂G(β, F−1z (v), z)
∂F−1z (v)
(
u− eδ′wE(U/eδ′W )
)′
γi
+
∂G(β, F−1z (v), z)
∂F−1z (v)
(F−1z (v)− γ′u) (w − E(W ))′ δi
√
n(Rˆz(v)−Rz(v)) and √n(Rˆ−1z (p)−R−1z (p)) converge in distribution to mean 0 normal
random variables with variances
σ2z(v) =
(
∂Rz(v)
∂β
)
Σ(β)
(
∂Rz(v)
∂β
)T
+ var(Ψ1z), and
τ 2z (p) =
(
∂R−1z (p)
∂p
)2
σ2z(v),
for v = R−1z (p) respectively. These expressions reduce to those of Theorems 1 and 2 when
no covariates are modeled.
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Table 1
Results of 5,000 simulations to evaluate the application of inference based on asymptotic
theory to finite sample studies. Box-Cox risk with β0 = −0.486, β1 = 0.793, β2 = 0.4, the
same as in Table 2. Shown are results for Rˆ(v)
v = 0.1 v = 0.3 v = 0.5 v = 0.7 v = 0.9
R(v) 0.100 0.194 0.313 0.491 0.800
Bias
% bias in Rˆ(v)
n = 100 −1.636 −3.058 −0.969 −0.493 −0.749
n = 500 −0.164 −0.619 −0.468 −0.308 −0.031
n = 2000 −0.279 −0.240 −0.152 −0.095 −0.033
Variance
Asymptotic − Observed
Observed %
n = 100 −7.660 −11.976 −4.646 −7.322 7.262
n = 500 3.276 1.103 −0.875 −1.694 −3.330
n = 2000 0.538 −0.200 1.739 0.047 5.910
95% Confidence Interval
coverage (%)
n = 100 86.529 92.094 92.914 92.874 89.992
n = 500 92.984 94.769 94.567 94.386 94.245
n = 2000 94.238 95.038 95.428 95.161 95.346
21
Hosted by The Berkeley Electronic Press
Table 2
Results of simulations to evaluate the application of inference based on asymptotic theory to
finite sample studies. Box-Cox risk with β0 = −0.486, β1 = 0.793, β2 = 0.4, the same as in
Table 1. Shown are results for Rˆ−1(p)
p = 0.1 p = 0.3 p = 0.5 p = 0.7 p = 0.9
R−1(p) 0.100 0.480 0.708 0.848 0.944
Bias
% bias in Rˆ−1(p)
n = 100 20.292 0.821 −0.892 −0.800 −0.746
n = 500 0.795 0.500 −0.096 −0.156 −0.199
n = 2000 0.316 0.154 0.0008 −0.034 −0.031
Variance
Asymptotic − Observed
Observed %
n = 100 37.008 7.548 5.396 −9.196 −0.409
n = 500 11.167 1.173 −0.018 −1.133 3.857
n = 2000 1.249 1.730 1.134 4.121 6.095
95% Confidence Interval
coverage (%)
n = 100 73.46 92.11 92.01 94.06 91.23
n = 500 91.33 93.60 94.08 95.09 95.53
n = 2000 94.20 94.77 94.65 95.71 95.86
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Table 3
Point estimates and 95% confidence intervals for R(v) and R−1(p) using −FEV1 and
−weight as markers of risk for subsequent pulmonary exacerbation in patients with cystic
fibrosis.
Estimate Variance Confidence Interval Confidence Interval
due to Fˆ Asymptotic Bootstrap
R(0.9)
FEV1 0.76 10.0% (0.748,0.779) (0.749,0.779)
weight 0.58 0.60% (0.568,0.601) (0.567,0.601)
R(0.1)
FEV1 0.15 8.91% (0.133,0.157) (0.133,0.157)
weight 0.28 0.72% (0.262,0.293) (0.261,0.294)
R−1(0.25)
FEV1 0.29 18.16% (0.273,0.311) (0.270,0.314)
weight 0 0% (0,0.040) (0,0.039)
R−1(0.75)
FEV1 0.88 13.58% (0.865,0.897) (0.864,0.898)
weight 1 0% (1,1) (1,1)
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Figure 1. Predictiveness curves for two markers of pulmonary exacerbation in children with
cystic ﬁbrosis. F is the cdf of the marker. The x-axis concerns the marker quantile and the
y-axis shows the corresponding risk, R(v) = P [D = 1|Y = F−1(v)]
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Figure 2. Predictiveness curves for lung function as a predictor of risk of pulmonary
exacerbation in the subsequent year. Shown are curves for cystic ﬁbrosis children with poor,
average and good nutritional status deﬁned by weight at the 1st, 2nd and 3rd quartiles, the
incidences of pulmonary exacerbation in the 3 groups being 0.58, 0.40 and 0.30, respectively.
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Figure 3. Predictiveness of PSA and PSA velocity as markers for prostate cancer risk. The
top panel is for all cancers while the bottom panel is for the subset of high grade cancers
(Gleason score > 6). The horizontal lines show the prevalence of cancer and correspond to
predictiveness curves of a useless marker.
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